Clinical Trials

Have you or your child been diagnosed with cystic fibrosis, and would you like to support better diagnosis of lung infections? This study is exploring new ways to diagnose bacterial lung infections in people who have cystic fibrosis. The study will test whether analyzing a participant’s breath and sputum samples can help diagnose infections. Participants in this study must be at least 3 years old. This study is taking place in multiple locations in the United States.

Are you a healthy adult or an adult who has been diagnosed with an interstitial lung disease (ILD)? This study will test whether administering an inhaled gas called hyperpolarized 129Xe before magnetic resonance imaging (MRI) better detects changing disease activity. To participate in the study, you must be age 18 or older and have no history of smoking for the past 5 years. This study will take place in Iowa City, Iowa; Cincinnati, Ohio; and Durham, North Carolina.

Are you a woman 18 years old or older who has been diagnosed with LAM? This study is examining whether long-term treatment with medicine called sirolimus can stop lung damage in women who have LAM. This study takes place at multiple locations in the United States.

Are you between 14 and 22 weeks pregnant, and think that you might have obstructive sleep apnea (OSA) ? This study is testing whether using CPAP to treat obstructive sleep apnea in pregnant women can help lower the risk of hypertensive disorders during pregnancy. To participate in this study, you must be at least 18 years old. This study takes place in multiple locations in the United States.

Do you have a child with Down syndrome and obstructive sleep apnea who is treated with positive airway pressure (PAP)? This study is testing a new intervention that was informed by the families to help children with Down syndrome and obstructive sleep apnea stick to their PAP treatment. The study will test the effectiveness of a new treatment plan that involves regular telephone and in-person check-ins with a PAP specialist. This study is for 6 -18 year old and is located in Cincinnati, Ohio; and Philadelphia, Pennsylvania.

This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.

The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.

Do you or your child have Friedrich's Ataxia? This study is looking into a supplement in the form of vitamin B3 plus exercise can help the body better use oxygen for people with Friedrich’s Ataxia. You must be 10 to 40 years old to join. Participants may be asked to take the daily supplement, exercise, or do both during the study. The study is taking place in Philadelphia, Pennsylvania.

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.

Investigators will conduct in-human PET imaging of 18F-fluoroglutamine (18F-FGln) in patients with PAH to compare glutamine uptake to that of controls.